FDA Approves Aqneursa for Ataxia-Telangiectasia

Company IntraBio Event Type FDA Approval (Indication Expansion) Modality Small Molecule (L-Enantiomer of Acetylleucine) Asset Aqneursa (Levacetylleucine) Disease Area Ataxia-Telangiectasia (Neurologic Manifestations) Summary FDA expanded Aqneursa, levacetylleucine, to treat ataxia in adults and children with ataxia-telangiectasia who weigh at least 15 kilograms. It is the…